Crohn’s Disease | Disease Landscape and Forecast | G7 | 2019

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie / Eisai’s Humira), together with newer therapies (i.e., Takeda’s Entyvio, a CAM inhibitor, and Janssen’s Stelara, an IL-12/23 inhibitor), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs’ efficacy limitations (e.g., patients lose response over time) and safety risks. The impending entry of several new therapies offering more-convenient formulations and/or novel mechanisms of action (e.g., Galapagos / Gilead’s filgotinib, TiGenix / Takeda’s Alofisel, AbbVie’s risankizumab and upadacitinib, Celgene’s ozanimod) will further improve treatment and intensify market competition. In balance with these trends, the continuing generic erosion of conventional agents and the availability of less-expensive biosimilar TNF-alpha inhibitors will constrain CD therapy sales.


  • What are KOLs’ opinions of current treatment options (e.g., Remicade, Humira, Stelara, Entyvio)? How have biosimilars influenced treatment practices? What factors drive treatment decisions?
  • What do KOLs think about emerging therapies (e.g., filgotinib, risankizumab, upadacitinib, ozanimod)? What impact will stem-cell therapy and oral therapies have on the CD treatment algorithm?
  • Which emerging agents are likely to be most successful in targeting TNF-refractory patients and gaining uptake in the CD market?
  • How will the market evolve over the next ten years?


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Login to access report